Showing 1461-1470 of 1775 results for "".
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- I-MED Pharma Becomes Authorized Canadian Distributor for OrCam MyEye 2https://modernod.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/I-MED Pharma, a Canadian company specializing in dry eye diagnosis and management, announced the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired. The OrCam MyEye 2 is a tiny, portable, artif
- OneSight Seeks Volunteer ODs for Charitable Clinicshttps://modernod.com/news/onesight-seeks-volunteer-ods-for-charitable-clinics/2479133/OneSight, which provides vision care access to more than 50 million people globally through charitable vision clinics and permanent vision centers, is in need of optical professionals to volunteer their skills to help reach the 1.1 billion people worldwide who lack access to eye exams and glasses
- NTC and I-MED Pharma Partner to Bring HA-based Dry Eye Ointment to the United States Markethttps://modernod.com/news/ntc-and-i-med-pharma-partner-to-bring-ha-based-dry-eye-ointment-to-the-united-states-market/2480516/NTC Srl and I-MED Pharma announced today that I-Defense, a lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the FDA. It is the first European NTC medical device prod
- New England College of Optometry to Launch Hybrid OD Teaching and Training Programhttps://modernod.com/news/new-england-college-of-optometry-to-launch-hybrid-od-teaching-and-training-program/2480337/
- First-Hand Accounts From ODs Who Tested Positive With COVID-19https://modernod.com/news/first-hand-accounts-from-ods-who-tested-positive-with-covid-19/2477530/
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- AOA Announces 2019 National Optometry Hall of Fame Inducteeshttps://modernod.com/news/aoa-announces-2019-national-optometry-hall-of-fame-inductees/2476443/The American Optometric Association has announced the four ODs who will be inducted into the National Optometry Hall of Fame in 2019. This year’s inductees are: Murray Fingeret, OD; Donald Jarnagin, OD; Michael Mittelman, OD; and Glen Steele, OD.
- Visus Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-presents-topline-clinical-data-from-phase-3-pivotal-brio-i-trial-of-brimochol-pf-for-the-treatment-of-presbyopia-at-eyecelerator-at-ascrs-2023/2481595/Visus Therapeutics presented key topline data from the pivotal phase 3 BRIO-I clinical trial. The study evaluating the safety and efficacy of Brimochol PF, a preservative-free ophthalmic solution for the treatment of presbyopia, met its primary and secondary endpoints. Brimoch